Ruitao Lin, Ph.D.

Peer-Reviewed Articles

1. Han Y, Shi H, Cao J, Lin R. Drift Parameter Based Sample Size Determination in Multi-Stage Bayesian Randomized Clinical Trials. Pharm Stat 24(5):e70037, 2025. e-Pub 2025. PMID: 40810309.
2. Chi X, Yuan Y, Lin R. BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations. Ther Innov Regul Sci, 2025. e-Pub 2025. PMID: 40830695.
3. Yeboa DN, Li J, Lin R, Prabhu SS, Beckham TH, Woodhouse K, Swanson TA, Weinberg JS, Wang X, Chi X, Ejezie CL, Suki D, Wang C, Ene C, McCutcheon IE, McGovern S, McAleer MF, Tom M, Ghia A, Perni S, Jiang W, De B, Chung C, Kim BYS, O'Brien BJ, Huse JT, Wefel JS, Court L, Tawbi H, Janku F, Guha-Thakurta N, Debnam JM, Johnson J, Taslicay CA, Alvarez-Breckenridge C, Raza SM, Heimberger AB, DeMonte F, North R, Briere TM, de Groot JF, Sawaya R, Grosshans D, Lang FF, Rao G, Ferguson SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncol 11(8):890-899, 2025. e-Pub 2025. PMID: 40531511.
4. Chen K, Chen TY, Zhang Y, Lin R, Yuan Y. Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials. Clin Cancer Res 31(13):2573-2580, 2025. e-Pub 2025. PMID: 40327336.
5. Zhang J, Zhou H, Wages NA, Guo Z, Liu F, Jemielita T, Yan F, Lin R. TODO: A Triple-Outcome Double-Criterion Optimal Design for Dose Monitoring-and-Optimization in Multi-Dose Randomized Trials. Stat Med 44(10-12):e70090, 2025. e-Pub 2025. PMID: 40390185.
6. Tian F, Lin R, Liu S, Yuan Y. Sample-size determination for decentralized clinical trials. Int J Epidemiol 54(3), 2025. e-Pub 2025. PMID: 40393699.
7. Chi X, Lin R, Yuan Y. COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics 81(2), 2025. e-Pub 2025. PMID: 40552493.
8. Nastoupil LJ, Andersen CR, Ayers A, Wang Y, Habermann TM, Chihara D, Kahl BS, Link BK, Koff JL, Cohen JB, Martin P, Lossos IS, Stanchina M, Haddadi S, Casulo C, Ayyappan S, Lin R, Li Z, Larson MA, Maurer MJ, Huynh L, Gao C, Ramasubramanian R, Duh MS, Mutebi A, Wang T, Jun M, Wang A, Kamalakar R, Kalsekar A, Cerhan JR, Flowers CR. Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 25(4):e183-e199.e8, 2025. e-Pub 2025. PMID: 39966020.
9. Yan Y, Lin R, Guan T, Shi H, Lin X. A Generalized Phase I/II Dose Optimization Trial Design With Multi-Categorical and Multi-Graded Outcomes. Stat Med 44(7):e70049, 2025. e-Pub 2025. PMID: 40213898.
10. Cheng, G, Hu, W, Lin, R, Wang, C. Online robust estimation and bootstrap inference for function-on-scalar regression. Statistics and Computing 35(1), 2025. e-Pub 2025.
11. Wages, NA, Lin, R. Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes. Statistics in Biopharmaceutical Research 17(1):36-45, 2025. e-Pub 2025.
12. Lu M, Zhang J, Yuan Y, Lin R. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials. Stat Biopharm Res 17(2):266-276, 2025. e-Pub 2025. PMID: 40321359.
13. Wages NA, Lin R. Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes. Stat Biopharm Res 17(1):36-45, 2025. e-Pub 2025. PMID: 40842959.
14. Zhang, J, Wages, NA, Lin, R. SFU: Surface-Free Utility-Based Design for Dose Optimization in Cancer Drug Combination Trials. Statistics in Biosciences 16(3):854-881, 2024. e-Pub 2024.
15. Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res 30(20):4791-4799, 2024. e-Pub 2024. PMID: 39133081.
16. Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant, 2024. e-Pub 2024. PMID: 39341929.
17. Cheng, G, Xiong, Q, Lin, R. Online bootstrap inference for the geometric median. Computational Statistics and Data Analysis 197, 2024. e-Pub 2024.
18. Mitchell KG, Feldman H, Milton DR, Antonoff MB, Hofstetter WL, Rice DC, Vaporciyan AA, Lin R, Thall PF, Rajaram R. Signet ring cells and conditional survival after trimodality therapy for esophageal adenocarcinoma. J Surg Oncol 130(3):428-434, 2024. e-Pub 2024. PMID: 39004940.
19. Cata JP, Zaidi Y, Guerra-Londono JJ, Kharasch ED, Piotrowski M, Kee S, Cortes-Mejia NA, Gloria-Escobar JM, Thall PF, Lin R. Intraoperative methadone administration for total mastectomy: A single center retrospective study. J Clin Anesth 98:111572, 2024. e-Pub 2024. PMID: 39180867.
20. Yang CH, Kwiatkowski E, Lee JJ, Lin R. REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors. Stat Med 43(18):3484-3502, 2024. e-Pub 2024. PMID: 38857904.
21. Lin LL, Wong F, Lin R, Yap T, Litton JK. Pharmacodynamic Activity of [(18)F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib. JCO Precis Oncol 8:e2400303, 2024. e-Pub 2024. PMID: 39208372.
22. Mulier G, Lin R, Aparicio T, Biard L. Bayesian sequential monitoring strategies for trials of digestive cancer therapeutics. BMC Med Res Methodol 24(1):154, 2024. e-Pub 2024. PMID: 39030498.
23. Tino R, Roach MA, Fuentes GD, Agrawal A, Zaid M, Cooper DJ, Bajaj N, Lin R, Xiao L, Mayo LL, Wiederhold LR, Shah SJ, Tate MK, Chronowski GM, Reddy JP, Mezera M, Mann JM, Augspurger M, Otun AO, Chambers MS, Koay EJ. Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy. Oral Oncol 157:106944, 2024. e-Pub 2024. PMID: 39024700.
24. Yang P, Li D, Lin R, Huang B, Yuan Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Stat Med 43(15):2972-2986, 2024. e-Pub 2024. PMID: 38747472.
25. Cheng G, Lin R, Peng L. High-dimensional multivariate analysis of variance via geometric median and bootstrapping. Biometrics 80(3), 2024. e-Pub 2024. PMID: 39248122.
26. Yang CH, Cheng G, Lin R. On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies. Pharm Stat 23(4):585-594, 2024. e-Pub 2024. PMID: 38317370.
27. Zhang J, Lin R, Chen X, Yan F. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clin Trials 21(3):308-321, 2024. e-Pub 2024. PMID: 38243401.
28. Tian F, Lin R, Wang L, Yuan Y. A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Stat Methods Med Res 33(6):931-944, 2024. e-Pub 2024. PMID: 38573788.
29. Yoder AK, Xu T, Youssef P, DeSnyder S, Marqueen KE, Isales L, Lin R, Smith BD, Woodward WA, Stauder MC, Strom EA, Aldrich MB, Shaitelman SF. Association Between Symptom Burden and Early Lymphatic Abnormalities After Regional Nodal Irradiation for Breast Cancer. Pract Radiat Oncol 14(3):e180-e189, 2024. e-Pub 2024. PMID: 37914083.
30. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
31. Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Cetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv 10(11):eadd9342, 2024. e-Pub 2024. PMID: 38478609.
32. Chi X, Yuan Y, Yu Z, Lin R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biom J 66(2):e2300122, 2024. e-Pub 2024. PMID: 38368277.
33. Liu, R, Yuan, Y, Sen, S, Marchenko, O, Jiang, Q, Tian, H, Li, X, Lin, R, Lu, C, Zhou, H. Design Strategy and Consideration for Oncology Dose-Optimization. Statistics in Biopharmaceutical Research 16(3):338-347, 2024. e-Pub 2024.
34. Mulier G, Chevret S, Lin R, Biard L. Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints. Stat Biopharm Res 16(3):315-325, 2024. e-Pub 2024. PMID: 39301054.
35. Zhang J, Yan F, Wages NA, Lin R. Local continual reassessment methods for dose finding and optimization in drug-combination trials. Stat Methods Med Res 32(10):2049-2063, 2023. e-Pub 2023. PMID: 37593951.
36. Long, Z, Li, Z, Lin, R, Qiu, J. On singular values of large dimensional lag-τ sample auto-correlation matrices. Journal of Multivariate Analysis 197, 2023. e-Pub 2023. PMID: 37388905.
37. Salama V, Youssef S, Xu T, Wahid KA, Chen J, Rigert J, Lee A, Hutcheson KA, Gunn B, Phan J, Garden AS, Frank SJ, Morrison W, Reddy JP, Spiotto MT, Naser MA, Dede C, He R, Mohamed ASR, van Dijk LV, Lin R, Roldan CJ, Rosenthal DI, Fuller CD, Moreno AC. Temporal characterization of acute pain and toxicity kinetics during radiation therapy for head and neck cancer. A retrospective study. Oral Oncol Rep 7, 2023. e-Pub 2023. PMID: 38638130.
38. Xu, T, Shi, H, Lin, R. Bayesian single-to-double arm transition design using both short-term and long-term endpoints. Pharmaceutical statistics 22(4):588-604, 2023. e-Pub 2023. PMID: 36755420.
39. Li, R, Altan, M, Reuben, A, Lin, R, Heymach, JV, Tran, HT, Chen, R, Little, L, Hubert, SM, Zhang, J, Li, Z. A novel statistical method for decontaminating T-cell receptor sequencing data. Briefings in bioinformatics 24(4), 2023. e-Pub 2023. PMID: 37337757.
40. Moreno, AC, Solanki, AA, Xu, T, Lin, R, Palta, JR, Daugherty, E, Hong, D, Hong, JC, Kamran, SC, Katsoulakis, E, Brock, K, Feng, M, Fuller, C, Mayo, C, Consortium, BC. Identification of Key Elements in Prostate Cancer for Ontology Building via a Multidisciplinary Consensus Agreement. Cancers 15(12), 2023. e-Pub 2023. PMID: 37370731.
41. Naser, M, Wahid, K, Ahmed, S, Salama, V, Dede, C, Edwards, BW, Lin, R, McDonald, B, Salzillo, TC, He, R, Ding, Y, Abdelaal, MA, Thill, D, O'Connell, N, Willcut, V, Christodouleas, JP, Lai, SY, Fuller, C, Mohamed, AS. Quality assurance assessment of intra-acquisition diffusion-weighted and T2-weighted magnetic resonance imaging registration and contour propagation for head and neck cancer radiotherapy. Medical physics 50(4):2089-2099, 2023. e-Pub 2023. PMID: 36519973.
42. Lin R, Yin G, Shi H. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials. Biostatistics 24(2):277-294, 2023. e-Pub 2021. PMID: 34296266.
43. Glitza, IC, Ferguson, SD, Bassett Jr, R, Foster, AP, John, I, Hennegan, TD, Rohlfs, ML, Richard, J, Iqbal, M, Dett, TK, Lacey, C, Jackson, N, Rodgers, TE, Phillips, S, Duncan, S, Haydu, LE, Lin, R, Amaria, RN, Wong, MK, Diab, A, Yee, C, Patel, SP, McQuade, JL, Fischer, G, McCutcheon, IE, O'Brien, BJ, Tummala, S, Debnam, JM, Guha-Thakurta, N, Wargo, J, Burton, EM, Tawbi, H, Davies, MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease. Nature medicine 29(4):898-905, 2023. e-Pub 2023. PMID: 36997799.
44. Gandhi, A, Xu, T, DeSnyder, SM, Smith, GL, Lin, R, Barcenas, CH, Stauder, MC, Hoffman, K, Strom, EA, Ferguson, S, Smith, B, Woodward, W, Perkins, GH, Mitchell, MP, Garner, D, Goodman, C, Aldrich, MB, Travis, ML, Lilly, SE, Bedrosian, I, Shaitelman, SF. Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer. Breast 68:205-215, 2023. e-Pub 2023. PMID: 36863241.
45. Jiang, C, Liu, Y, Lian, J, Huang, S, Jordan, A, Cai, Q, Lin, R, Yan, F, McIntosh, J, Li, Y, Che, Y, Chen, Z, Vargas, J, Badillo, M, Bigcal, J, Lee, H, Wang, W, Yao, Y, Nie, L, Flowers, CR, Wang, L. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. Journal of Clinical Investigation 133(3), 2023. e-Pub 2023. PMID: 36719376.
46. Thall, PF, Zang, Y, Chapple, A, Yuan, Y, Lin, R, Marin, D, Msaouel, P. Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clinical Cancer Research 29(22):4549-4554, 2023. e-Pub 2023. PMID: 37725573.
47. Koutroumpakis, E, Xu, T, Lopez-Mattei, J, Pan, T, Lu, Y, Irizarry-Caro, JA, Mohan, R, Zhang, X, Meng, QH, Lin, R, Xu, T, Deswal, A, Liao, Z. Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. Frontiers in Cardiovascular Medicine 9, 2022. e-Pub 2022. PMID: 36531700.
48. Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials. Ann Appl Stat 16(4):2481-2504, 2022. e-Pub 2022. PMID: 36329718.
49. Chi X, Yu Z, Lin R. BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints. Stat Med 41(26):5319-5334, 2022. e-Pub 2022. PMID: 36127794.
50. Chihara D, Lin R, Flowers CR, Finnigan SR, Cordes LM, Fukuda Y, Huang EP, Rubinstein LV, Nastoupil LJ, Ivy SP, Doroshow JH, Takebe N. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400(10351):512-521, 2022. e-Pub 2022. PMID: 35964611.
51. Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med 41(11):1918-1931, 2022. e-Pub 2022. PMID: 35098585.
52. Liu, R, Yuan, Y, Sen, S, Yang, X, Jiang, Q, Li, X, Lu, C, Gönen, M, Tian, H, Zhou, H, Lin, R, Marchenko, O. Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research 14(3):270-282, 2022. e-Pub 2022. PMID: 37275462.
53. Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, Lopez-Mattei JC, Mohan R, Liao Z. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys 111(4):907-916, 2021. e-Pub 2021. PMID: 34302893.
54. Zhou Y, Lin R, Lee JJ. The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. Pharm Stat 20(6):1183-1199, 2021. e-Pub 2021. PMID: 34008317.
55. Lin R, Chan KG, Shi H. A unified Bayesian framework for exact inference of area under the receiver operating characteristic curve. Stat Methods Med Res 30(10):2269-2287, 2021. e-Pub 2021. PMID: 34468238.
56. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
57. Wen YF, Chen MX, Yin G, Lin R, Zhong YJ, Dong QQ, Wong HM. The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990-2019: a population-based study. J Hematol Oncol 14(1):89, 2021. e-Pub 2021. PMID: 34108026.
58. Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Stat Med 40(11):2626-2649, 2021. e-Pub 2021. PMID: 33650708.
59. Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal 16(1):179-202, 2021. e-Pub 2021. PMID: 34267857.
60. Zou, T, Lin, R, Zheng, S, Tian, GL. Two-sample tests for high-dimensional covariance matrices using both difference and ratio. Electronic Journal of Statistics 15(1):135-210, 2021. e-Pub 2021.
61. Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform 5:91-101, 2021. e-Pub 2021. PMID: 33439726.
62. Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials 100:106216, 2021. e-Pub 2021. PMID: 33246098.
63. Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc 116(533):322-334, 2021. e-Pub 2021. PMID: 35582047.
64. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
65. Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics 21(4):807-824, 2020. e-Pub 2020. PMID: 30984972.
66. Park Y, Lin R. Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan. Biometrics 76(2):595-598, 2020. e-Pub 2020. PMID: 32251522.
67. Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials 92:105972, 2020. e-Pub 2020. PMID: 32151751.
68. Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76(1):304-315, 2020. e-Pub 2020. PMID: 31273750.
69. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst 112(1):38-45, 2020. e-Pub 2020. PMID: 30924863.
70. Zheng S, Lin R, Guo J, and Yin G. Testing homogeneity of high-dimensional covariance matrices. Statistica Sinica 30(1), 2020. e-Pub 2020.
71. Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 33283133.
72. Lam, CK, Lin, R, Yin, G. Non-parametric overdose control for dose finding in drug combination trials. Journal of the Royal Statistical Society. Series C: Applied Statistics 68(4):1111-1130, 2019. e-Pub 2019.
73. Lam CK, Lin R, and Yin G. Non‐parametric overdose control for dose finding in drug combination trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 68(4):1111-1130, 2019. e-Pub 2019.
74. Zheng, S, Lin, R, Guo, J, Yin, G. Testing homogeneity of high-dimensional covariance matrices. Statistica Sinica 30:35-53, 2019. e-Pub 2019.
75. Zhong YJ, Wen YF, Wong HM, Yin G, Lin R, Yang SY. Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. Front Oncol 9(MAY):404, 2019. e-Pub 2019. PMID: 31214489.
76. Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat 29(4):648-662, 2019. e-Pub 2019. PMID: 31258039.
77. Lin R. Bayesian optimal interval design with multiple toxicity constraints. Biometrics 74(4):1320-1330, 2018. e-Pub 2018. PMID: 29870069.
78. Lin R, Yin G. Uniformly most powerful Bayesian interval design for phase I dose-finding trials. Pharm Stat 17(6):710-724, 2018. e-Pub 2018. PMID: 30066466.
79. Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24(20):4921-4930, 2018. e-Pub 2018. PMID: 29769209.
80. Lin R, Yin G. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Stat Med 36(26):4106-4120, 2017. e-Pub 2017. PMID: 28786138.
81. Lin R, Yin G. Bayesian optimal interval design for dose finding in drug-combination trials. Stat Methods Med Res 26(5):2155-2167, 2017. e-Pub 2017. PMID: 26178591.
82. Lin R, Yin G. Nonparametric overdose control with late-onset toxicity in phase I clinical trials. Biostatistics 18(1):180-194, 2017. e-Pub 2017. PMID: 27549121.
83. Lin, R, Liu, Z, Zheng, S, Yin, G. Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics and Data Analysis 104:10-23, 2016. e-Pub 2016.
84. Lin, R, Yin, G. Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. Annals of Applied Statistics 10(4):2349-2376, 2016. e-Pub 2016.
85. Lin R, Liu Z, Zheng S, Yin G. Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics & Data Analysis 104:10-23, 2016. e-Pub 2016.
86. Lin R, Yin G. Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials. The Annals of Applied Statistics 10:2349-2376, 2016. e-Pub 2016.
87. Lin R, Yin G. Bayes factor and posterior probability: Complementary statistical evidence to p-value. Contemp Clin Trials 44:33-35, 2015. e-Pub 2015. PMID: 26212520.
88. Yin G, Lin R. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar. Stat Med 34(1):13-7, 2015. e-Pub 2015. PMID: 25492615.
89. Wen YF, Wong HM, Lin R, Yin G, McGrath C. Inter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric Studies. PLoS One 10(8):e0134525, 2015. e-Pub 2015. PMID: 26247212.

Review Articles

1. Shi H, Lin R, Lin X. Comparative review of novel model-assisted designs for phase I/II clinical trials. Biom J 66(4):e2300398, 2024. e-Pub 2024. PMID: 38738318.
2. Ananthakrishnan R, Lin R, He C, Chen Y, Li D, LaValley M. An overview of the BOIN design and its current extensions for novel early-phase oncology trials. Contemp Clin Trials Commun 28:100943, 2022. e-Pub 2022. PMID: 35812822.

Other Articles

1. Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 30(6):1787, 2024. PMID: 38649781.
2. Olson AL, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Li L, Abueg G, Timmons M, Chemaly R, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones RB, Andersson BS, Oran B, Abuddayeh A, Popat U, Champlin RE, Shpall EJ, Rezvani K Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood 134(Suppl 1), 2019.

Book Chapters

1. Lin R, Lee JJ. Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. In: Computational and Methodological Statistics and Biostatistics. Springer, 2020.
2. Yuan Y, Lin R. Novel Designs for Early Phase Drug Combination Trials. In: Bayesian Applications in Pharmaceutical Development. Chapman and Hall/CRC, 2019.
3. Lin, R, Yin, G. Random walk and parallel crossing bayesian optimal interval design for dose finding with combined drugs, 21-35, 2017.
4. Lin R, Yin G. Random Walk and Parallel Crossing Bayesian Optimal Interval Design for Dose Finding with Combined Drugs. In: Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017.
5. Lin R, Yin G. Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials. In: Advanced Statistical Methods in Data Science. Springer, Singapore, 2016.
6. Lin, R, Yin, G. Sample size re-estimation in adaptively randomized clinical trials with missing data, 269-285, 2015.
7. Yin G, Lin R. Continual reassessment methods. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.
8. Lin R, Yin G. Sample size re-estimation in adaptively randomized clinical trials with missing data. In: Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. Chapman and Hall/CRC, 2015.
9. Lin R, Yin G. Adaptive randomization. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.

Books (edited and written)

1. Yuan Y, Lin R, Lee JJ. Model-Assisted Bayesian Designs for Dose Finding and Optimization: Methods and Applications. CRC Press, 2022.

Letters to the Editor

1. Tino RB, Roach MA, Fuentes GD, Agrawal A, Zaid M, Cooper DJ, Bajaj N, Lin R, Xiao L, Mayo LL, Wiederhold LR, Shah SJ, Tate MK, Chronowski GM, Reddy JP, Mezera M, Mann JM, Augspurger M, Otun AO, Chambers MS, Lee A, Koay EJ. Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy". Oral Oncol 162: 107220, 2025.